U.S. flag An official website of the United States government
  1. Home
  2. Tobacco Products
  3. Tobacco Science & Research
  4. Research
  5. A Mouse Model of Vaping Vitamin E Acetate: Effects on Lung Function and Pathology
  1. Research

A Mouse Model of Vaping Vitamin E Acetate: Effects on Lung Function and Pathology

Principal Investigator: Eliot Spindel

Funding Mechanism: National Institutes of Health - Grant

ID number: 3R01HL144384-02S1

Award Date: 7/17/2020

Institution: Oregon Health & Science University


In this CTP supplement to a parent grant (Effects of E-cigarette Exposure during Pregnancy on Offspring Lung Function and Disease: Characterization of Pulmonary, Intergenerational, and Epigenetic Effects), researchers will study the effects of inhaling vitamin E acetate (VEA) compared to aerosolized nicotine in propylene glycol/vegetable glycerol (PG/VG), which is linked to e-cigarette/vaping-associated lung injury (EVALI), on lung function and pathology in a mouse model. Study aims are: (1) to characterize the acute effects of vaping with increasing e-liquid percentage of VEA; and (2) to characterize the chronic effects of vaping VEA on lung function and pathology. To achieve Aim 1, researchers will expose mice that have not previously been exposed to vaping (naïve mice) and mice that have been exposed to house dust mite antigen (sensitized mice) or to aerosolized nicotine in PG/VG to increasing percentages (0, 10, 20, 40, or 80%) of VEA in PG/VG (1:1) e-liquid; researchers will determine VEA effects on pulse oximetry, bronchial lavage composition, and lung pathology compared to nicotine. At the optimal condition found to induce EVALI-like changes, researchers will determine the effects of modifying voltage. To achieve Aim 2, researchers will determine the chronic pulmonary effects of vaping (measured at 2 and 4 weeks) using a complete battery of pulmonary function tests, pulse oximetry, heart rate, bronchial lavage and lung pathology on naïve and sensitized mice. Study findings may inform the understanding of the link of pre-disposing factors, such as prior ENDS use, and pre-existing respiratory conditions, such as asthma, on the incidence of EVALI. 
 

Back to Top